Skip to Content


Treatment for Pseudobulbar Affect

Update: Nuedexta (dextromethorphan and quinidine) Now FDA Approved - October 29, 2010

Avanir Submits Expanded Neurodex New Drug Application for the Treatment of Involuntary Emotional Expression Disorder

SAN DIEGO, January 30, 2006 - Avanir Pharmaceuticals (AMEX:AVN.R) announced today that on Friday, January 27, 2006, it completed the submission of its new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Neurodex, seeking marketing approval of the drug candidate for the treatment of involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability. The application was resubmitted to the FDA to provide an expansion of certain summary analyses which better support the electronic common technical document (e-CTD) format.

The application is based on clinical data supporting that Neurodex, a combination of dextromethorphan and low dose quinidine, is safe and effective in reducing the frequency and severity of sudden and uncontrollable crying and/or laughing episodes that occur as a consequence of neurological disease or injury. Avanir has formally requested priority review status from the FDA for this application. If the FDA grants Avanir's priority review request, the date for the agency to take action on the application will be six months from the filing date. If standard review status is granted, a review time of ten months will apply to the application.

"We are very pleased to announce this important submission. While the FDA's request was limited to reorganization and expanded discussions of existing data within the electronic document, we took the time to include additional safety data rather than providing it as a separate supplemental filing as originally planned. The additional safety data are consistent with the data previously submitted," said Eric K. Brandt, President and Chief Executive Officer of Avanir. "We feel the application is strengthened, and look forward to hearing from the FDA over the next sixty days regarding the fileability status and the review designation granted for our application."

For more information, please visit Avanir Pharmaceuticals

Posted: January 2006

Related Articles

Nuedexta (dextromethorphan and quinidine) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.